3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
89
Leukemia
68
Precursor Cell Lymphoblastic Leukemia-Lymphoma
36
Lymphoma
26
Leukemia, Erythroblastic, Acute
19
Leukemia, Myelomonocytic, Acute
18
Leukemia, Monocytic, Acute
18
Leukemia, Megakaryoblastic, Acute
18
Congenital Abnormalities
13
Burkitt Lymphoma
13
Lymphoma, Large B-Cell, Diffuse
12
Myelodysplastic Syndromes
10
Lymphoma, Non-Hodgkin
10
Anemia, Refractory, with Excess of Blasts
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lymphoma, Follicular
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Eosinophilic, Acute
6
Recurrence
5
Myeloproliferative Disorders
5
Lymphoma, Large-Cell, Immunoblastic
5
Leukemia, Promyelocytic, Acute
5
Leukemia, Biphenotypic, Acute
5
Leukemia, Basophilic, Acute
5
Hodgkin Disease
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Myelodysplastic-Myeloproliferative Diseases
4
Multiple Myeloma
4
Interventions
Dexamethasone
2
Bortezomib
2
ponatinib
1
pegaspargase
1
isatuximab
1
ibrutinib
1
ibritumomab tiuxetan
1
cirmtuzumab
1
blinatumomab
1
asparaginase erwinia chrysanthemi recombinant
1
Vorinostat
1
Rituximab
1
Methotrexate
1
Melphalan
1
Lenalidomide
1
Imatinib Mesylate
1
Ifosfamide
1
Etoposide
1
Daunorubicin
1
Cytarabine
1
Carmustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Immunoproliferative Disorders
×
Cytarabine
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts